Given the known role of IL-17 in promoting early stage CRC development [1], and its negative impact in the inhibition of CD8+ CTLs and Tregs, blocking IL-17 may suppress tumor-promoting inflammation, activate tumor immunosurveillance, and reduce the rate of tumorigenesis in this genetically predisposed population. This evidence concerns the gene IL17A and colorectal carcinoma.